growth hormone-releasing hormone antagonists ͉ tumor receptors A ntagonists of growth hormone-releasing hormone (GHRH) were initially developed to block growth hormone (GH) secretion from the pituitary glands, leading to inhibition of insulin-like growth factor I (IGF-I) production in the liver and other tissues (1-6). The reduction in the levels of serum IGF-I could inhibit the proliferation of various cancers dependent on IGF-I, in view of involvement of this growth factor and of IGF-II, which is GH independent, in malignant transformation of cells, tumor progression, and metastasis (1-3). GHRH antagonists were shown to effectively inhibit the in vivo growth of various experimental human cancers, including osteosarcomas, mammary, ovarian and prostatic cancers, renal adenocarcinomas, small-cell lung cancer (SCLC) and non-SCLC, pancreatic and colorectal carcinomas, and malignant gliomas (7-17). The proliferation of some of these human cancers in vitro was also suppressed by GHRH antagonists (7-10, 12-14, 16-18). This finding and the reduction in the concentration of IGF-I and IGF-II and the suppression of the gene expression of IGF-I and -II in the tumors suggested that GHRH antagonists, in addition to indirect action mediated by inhibition of GH-IGF-I axis, might exert direct effects on tumor growth through specific yet-to-be-identified GHRH receptors (3, 19) .
A
ntagonists of growth hormone-releasing hormone (GHRH) were initially developed to block growth hormone (GH) secretion from the pituitary glands, leading to inhibition of insulin-like growth factor I (IGF-I) production in the liver and other tissues (1) (2) (3) (4) (5) (6) . The reduction in the levels of serum IGF-I could inhibit the proliferation of various cancers dependent on IGF-I, in view of involvement of this growth factor and of IGF-II, which is GH independent, in malignant transformation of cells, tumor progression, and metastasis (1) (2) (3) . GHRH antagonists were shown to effectively inhibit the in vivo growth of various experimental human cancers, including osteosarcomas, mammary, ovarian and prostatic cancers, renal adenocarcinomas, small-cell lung cancer (SCLC) and non-SCLC, pancreatic and colorectal carcinomas, and malignant gliomas (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) . The proliferation of some of these human cancers in vitro was also suppressed by GHRH antagonists (7-10, 12-14, 16-18) . This finding and the reduction in the concentration of IGF-I and IGF-II and the suppression of the gene expression of IGF-I and -II in the tumors suggested that GHRH antagonists, in addition to indirect action mediated by inhibition of GH-IGF-I axis, might exert direct effects on tumor growth through specific yet-to-be-identified GHRH receptors (3, 19) .
The GHRH receptor is a G-protein-coupled transmembrane receptor found predominantly in the pituitary gland, and its mRNA has also been detected in rat placenta, kidney, testis, hypothalamus, and the gastrointestinal tract (20) (21) (22) (23) . Receptors for other GHRH-related peptides, such as vasoactive intestinal peptide (VIP) and secretin, also belong to the G-protein-linked superfamily and show homology to GHRH receptor proteins (23) . Although VIP receptors have been detected in various tumors and could be involved in the regulation of tumor growth (21, (24) (25) (26) , recent work showed that the antiproliferative effect of GHRH antagonists is exerted through a mechanism independent of VIP receptors (27) . When primers for human GHRH (hGHRH) receptor mRNA were used (27) , no expression of mRNA was found in LNCaP human prostatic and MiaPaCa-2 human pancreatic cancer cells (27) , in accordance with an earlier report on ovarian tumors (28) . In addition, specific binding sites for radioligand [His 1 , 125 I-Tyr 10 ,Nle 27 ]hGHRH(1-32)NH 2 could not be detected in human cancers (14, 17, 27) , although this radioligand is widely used for the characterization of pituitary GHRH receptors (29) (30) (31) . These observations indicate that peptide receptors on human tumors that respond to our GHRH antagonists should be different from the classic pituitary-type GHRH receptors.
In this study, we report the presence of high-affinity binding sites for GHRH antagonists on CAKI-1 human renal cell carcinoma (RCC). The binding characteristics were investigated by ligand competition assays, using 125 I-labeled GHRH antagonist JV-1-42 as a specific radioligand. These binding sites appear to be isoforms of hGHRH receptor, as demonstrated by reverse transcription (RT)-PCR, and are also distinct from the VIP receptors. In addition, studies on the in vivo binding of 125 I-JV-1-42 to CAKI-1 tumors and the inhibitory effects of a potent GHRH antagonist, JV-1-38, on the orthotopic growth of this human RCC are presented. obtained from California Peptide Research (Napa, CA). Potent VIP antagonist PG 97-269 was provided by P. Gourlet and P. Robberecht (33) . Na 125 I and 125 I-VIP were purchased from Amersham Pharmacia Biotech. All other peptides and chemicals, unless otherwise mentioned, were obtained from Sigma, Bachem, and R & D Systems.
Materials and Methods
Radioiodination. Iodinated derivatives of GHRH antagonist JV-1-42 were prepared by the Chloramine-T method as described (31) and purified by HPLC. The fractions corresponding to the mono-iodinated compound and identified by elution position, radioactivity, and UV peak were stored at Ϫ70°C for the in vitro and in vivo receptor studies. Because phosphate buffer precipitates JV-1-42 this buffer was avoided during radioiodination as well as collection and storage of 125 ]hGHRH(1-32)NH 2 as radioligands to membrane fractions of CAKI-1 RCC. In brief, for saturation binding analyses, membrane homogenates containing 40-160 g of protein were incubated in duplicate or triplicate with at least six concentrations of 125 I-labeled peptide, ranging from 0.005 to 0.4 nM in the presence or absence of excess unlabeled peptide (1 M) in a total volume of 300 l of binding buffer (50 mM Tris⅐HCl͞5 mM EDTA͞5 mM MgCl 2 ͞1% BSA͞30 g/ml bacitracin, pH 7.4) supplemented with protease inhibitors as mentioned above. In the displacement experiments, which also included the specificity experiments, 50-to 150-g portions of membrane homogenates were incubated in duplicate or triplicate with 60,000-80,000 cpm of radioligand and increasing concentrations (10 Ϫ12 to 10 Ϫ6 M) of nonradioactive peptides as competitors. We observed that adsorption of radiolabeled JV-1-42 to borosilicate glass, polystyrene, and polypropylene is relatively high (Ͼ30%) and irreversible. Thus, binding reactions were performed in silane-treated polypropylene tubes, where the nonspecific binding of 125 I-JV-1-42 to the assay tubes was less than 5%. After 1 h of incubation at room temperature, the tubes were immersed in ice-water, 250 l of the suspension was transferred into cold silane-treated polypropylene Microfuge tubes (Sigma), and centrifuged at 12,000 ϫ g for 2 min (Beckman J2-21 M) at 4°C, and the supernatant was removed. The pellet was washed and the bottoms of the tubes were cut off and their radioactivities were measured in a ␥ counter. Receptor binding of VIP was also performed with an in vitro ligand competition assay based on binding of 125 I-VIP to tumor membrane homogenates as described (35) . Incubation and binding conditions were as in the GHRH receptor studies, but the reactions were terminated by adding 250 l of ice-cold binding buffer to the polypropylene tubes, and the bound ligand was separated from free ligand by centrifugation.
RT-PCR Analysis of Human GHRH Receptor Splicing Variants in CAKI-1
Human RCC. Poly(A) ϩ RNA was isolated from human pituitary adenoma (as control tissue) and CAKI-1 RCC, then reverse transcribed and amplified by RT-PCR using the reagents and protocol of the GeneAmp RNA PCR Core kit (Perkin-Elmer) as described by Rekasi et al. (36) . Briefly, RT reaction was performed in a final volume of 20 l containing 1 g of poly(A) ϩ RNA, 2.5 M oligo(dT), 1 mM each dNTP, 1ϫ PCR buffer, 5 mM MgCl 2 , 1 unit͞l RNase inhibitor, and 2.5 units͞l Moloney murine leukemia virus reverse transcriptase. Five microliters of the RT reaction was used for each PCR amplification with three sets of primers that would amplify a common fragment of cDNAs of both human pituitary GHRH receptors and its splice variant-1 (SV 1 ) (E6͞E12), a fragment of cDNA of SV 1 only (I3-1͞E12), or a fragment of cDNA of human pituitary GHRH receptor only (E1͞E8) (see sequences and location of gene-specific primers in ref. 36 ). The PCR mixture included 1ϫ PCR buffer, 2 mM MgCl 2 , 1.0 M each primer, and 2.5 units͞100 l AmpliTaq DNA polymerase in a 25-l volume. A secondary PCR was subsequently carried out by using 5 l of diluted primary PCR product, 1.0 M each nested primer (E7͞E8 for E6͞E12 product, I3-2͞E8 for I3-1͞E12 product, and E3͞E4 for E1͞E8 product, respectively) in a total volume of 25 l (see cycle profiles in ref. 36 ). The secondary PCR products were electrophoresed on a 1.5% agarose gel, stained with 0.5 g͞ml ethidium bromide, visualized under UV light followed by scanning of the gel (AlphaImager 2200 Documentation and Analysis System, Alpha Innotech, San Leandro, CA). The various GHRH receptor splice variants were purified from the gel by using a NucleoTrap Gel Extraction Kit (CLONTECH) and sequenced.
Biodistribution of JV-1-42. Male athymic nude mice (Ncr nu͞nu; Frederick Cancer Research and Development Center of the National Cancer Institute, Frederick, MD), approximately 6 weeks old on arrival, were housed and fed as described (10, 34) . The CAKI-1 human RCC cell line (American Type Culture Collection) was maintained in culture and used to initiate growth of s.c. xenografts in donor animals as described (10, 34) . Radiolabeled JV-1-42 (approximately 2 Ci; 1 Ci ϭ 37kBq) was injected i.v. into the jugular vein of 8 nude mice bearing s.c. xenografts of CAKI-1 RCC. Animals were killed 3 min (n ϭ 4) and 60 min (n ϭ 4) after the injection. Body fluids and organs were dissected and weighed, and radioactivities were measured in a ␥ counter (Micromedic Systems, Huntsville, AL).
Inhibition of Tumor Growth in Vivo.
Male nude mice were implanted orthotopically with 10 mg of minced CAKI-1 tumor tissue suspended in 0.02 ml of RPMI medium 1640 under a capsule of the left kidney as described previously (34) . One week later, animals were randomly divided into two groups for treatment with JV-1-38 (20 g͞day s.c., n ϭ 8) or vehicle solution (0.1% DMSO in 10% aqueous propylene glycol, n ϭ 7). Mice were euthanized after 30 days and tumors specimens were excised. Tumor weight was calculated by subtracting the weight of the right (normal) kidney from the weight of the left kidney implanted with tumor. Mice were carefully checked under a dissecting microscope for the presence of gross metastases in lymph nodes and lungs. All animal studies were conducted in accordance with institutional ethical guidelines for the care and use of experimental animals.
Data Analysis. Specific ligand binding capacities and affinities were calculated by the Ligand-PC computerized curve-fitting program of Munson and Rodbard (37) as modified by McPherson (38) . To determine the types of receptor binding, equilibrium dissociation constants (K d values), and the maximal binding capacity of receptors (B max ), receptor binding data were also analyzed by the Scatchard method (39). The differences between groups were assessed with the Student two-tailed t test. P Ͻ 0.05 was considered statistically significant.
Results

GHRH Receptor Binding Studies.
The presence of specific GHRH binding sites and binding characteristics of radiolabeled GHRH antagonist JV-1-42 to membrane receptors on CAKI-1 human RCC were determined by ligand competition assays. We found that accurate results could be obtained at room temperature when GHRH binding reached equilibrium in about 60 min and within a range of 30-180 g of membrane protein (Fig. 1) . Analyses of the binding data revealed that the one-site model provided the best fit, indicating the presence of one class of high-affinity low-capacity GHRH receptors in membranes of CAKI-1 tumors. The single class of binding sites had a mean dissociation constant (K d ) of 0.25 Ϯ 0.03 nM with a mean maximal binding capacity (B max ) of 70.2 Ϯ 4.1 fmol͞mg of membrane protein as determined by computerized nonlinear curve-fitting and the Scatchard plot analyses of the GHRH binding data (Fig. 1 ) in CAKI-1 tumors. The binding of 125 I-JV-1-42 was found to be saturable, reversible, time-and temperature-dependent, and linear with protein concentration in CAKI-1 human RCC examined (some data not shown). There were no significant differences in the binding characteristics of receptors for GHRH in the membrane fractions prepared from cells cultured in medium or from tumor xenografts. The specificity of GHRH binding was demonstrated by competitive binding experiments using several peptides structurally related or unrelated to GHRH (Fig. 2) . The binding of radiolabeled JV-1-42 was completely displaced by increasing concentrations (10 Ϫ12 to 10 (Fig. 2) . Their affinity was more than one order of magnitude higher than that of native human GHRH or its N-terminal fragment hGHRH(1-29)NH 2 and agonistic analog [His (Fig. 2) .
Ligand competition assays using ]hGHRH(1-32)NH 2 as radioligand revealed a weak receptor binding in membrane fractions of CAKI-1 RCC. Because the signal was very low, the binding characteristics could not be calculated by curve-fitting programs.
VIP Receptor Binding Studies. High-affinity binding sites for VIP were also found in the membrane fractions of xenografts of CAKI-1 RCC. Radiolabeled VIP was bound to one class of binding sites with a mean K d of 0.89 Ϯ 0.14 nM and a mean B max of 183.5 Ϯ 2.6 fmol͞mg of protein (Fig. 3) . The binding of I-VIP was found to be reversible, time-and temperaturedependent, and linear with the membrane protein concentration (data not shown). To study the specificity of receptors for VIP, heterologous displacement experiments were also performed. VIP and its specific antagonists JV-1-53 and PG 97-269 showed the highest binding affinity to VIP receptors on CAKI-1 cancer cells (Fig. 4) . GHRH antagonists JV-1-36 and JV-1-38 displayed around two orders of magnitude lower affinity than the VIPrelated peptides. The other two GHRH antagonists tested, JV-1-42 and MZ-5-156, had negligible binding affinity for VIP receptors (Fig. 4) (Fig. 5) . In CAKI-1 human RCC, only a slight trace of the corresponding band could be detected after 40 cycles. Using primers for amplifying a common fragment of cDNAs of both human pituitary GHRH receptor and its SV 1 , we detected an intense 147-bp band in both human pituitary adenoma and CAKI-1 human RCC (Fig. 5) . Amplification with primers designed for intron 3 and exon 8 yielded a 720-bp, a 566-bp, and a 335-bp PCR product in various proportions in pituitary adenoma and CAKI-1 tumors. Sequence analyses of these three PCR fragments revealed different major open reading frames, which were identical with SV 1, SV 2 , and SV 4 of GHRH receptor isolated from other cancer cells (36) . All of the splice variants have a retained intronic sequence at their 5Ј end and lack the first three exons. The intronic sequence replacing the first three exons gives rise to a truncated Nterminal extracellular domain. The rest of the 720-bp SV 1 is identical to pituitary GHRH receptor. In the 566-bp GHRH receptor SV 2 , exon 7 was spliced out of the RNA, whereas in the 335-bp GHRH receptor SV 4 , exon 5 and exon 6 were missing in addition. In SV 2 and SV 4, the lack of exon 5, 6, and͞or 7 resulted in a 1-nucleotide upstream frameshift leading to a premature TGA stop codon in exon 8. RT-PCR analysis of mRNA of GHRH receptor and its splice variants in human pituitary adenoma and CAKI-1 human RCC. Poly(A) ϩ RNA was reverse transcribed and amplified in PCR with primers for exon 3-4 (group 1), exon 7-8 (group 2), and intron 3-exon 8 (group 3) of human GHRH receptor gene. The secondary PCR products were separated electrophoretically on 1.5% agarose gels and stained with ethidium bromide. The PCR products were of the expected size of 144 bp (exon 3-4) (group 1); 147 bp (exon 7-8) (group 2); as well as 720 bp, 566 bp, and 335 bp (intron 3-exon 8) (group 3). Lanes: M, 100-bp DNA molecular weight marker; P, human pituitary adenoma; C, CAKI-1 RCC; Ϫ, RT-negative control from the mixture of poly(A) ϩ RNA from human pituitary adenoma and CAKI-1 RCC. The radioactivity in the thyroid gland may reflect the uptake of free 125 I.
Inhibition of the Orthotopic Growth and the Development of Metas-
tases of CAKI-1 RCC. The treatment with daily injections of JV-1-38 was started 1 week after orthotopic implantation of CAKI-1 RCC. Thirty days later the mean weight of orthotopic tumors treated with JV-1-38 was 54.7 Ϯ 9.7 mg, corresponding to an 83% reduction (P Ͻ 0.01), as compared with control tumors, which measured 322.3 Ϯ 67.9 mg (Fig. 6A) . Five of seven control animals (71%) developed metastases into regional and distant lymph nodes (Fig. 6B) , whereas the incidence of lymphatic spread in mice given JV-1-38 was 25% (two of eight). The rate of lung metastases found in control group was 57%, whereas only one of eight animals (12%) treated with JV-1-38 developed metastases to the lungs (Fig. 6B ).
Discussion
Antagonists of GHRH are promising candidates for anticancer therapy (1) (2) (3) . GHRH antagonists (4-6) inhibit the growth of various human neoplasms such as prostatic, ovarian, mammary, renal, pancreatic, and colorectal cancers, osteosarcomas, small-cell lung cancer (SCLC) and non-SCLC, and malignant gliomas (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) . The mechanisms that mediate the antitumor effect of GHRH antagonists in vivo include the suppression of the pituitary GH͞he-patic IGF-I axis and inhibition of the autocrine͞paracrine production of IGF-I and -II in tumors (3, 7-11, 14, 16-19) . It was also shown that GHRH antagonists inhibit cell proliferation, suppress the production of IGF-II, and decrease the telomerase activity in various human cancer cell lines cultured in vitro (8, 9, 11, 13, 14, 18, 40) . Some evidence also suggests that GHRH antagonists can suppress tumor growth by mechanisms that are IGF-independent (12, 14) . These effects and direct actions on tumoral IGF-II are likely to be mediated through specific yet-to-be-identified GHRH receptors expressed on human tumors. This study reports the existence of GHRH binding sites in a human cancer. The receptors for GHRH antagonists on CAKI-1 RCC were characterized by radioligand binding studies and found to display saturability, specificity and reversibility, and dependence on time, temperature, and membrane protein concentration. The ]hGHRH(1-32)NH 2 was more than one order of magnitude lower than that of GHRH antagonists JV-1-36, JV-1-38, and MZ-5-156. GHRH is a member of the family of peptides that includes VIP, glucagon, secretin, gastric inhibitory peptide, and PACAP (3, 23 substitutions are present in both ligands (6) . GHRH antagonist JV-1-42, and other antagonists, such as JV-1-36, JV-1-38, and MZ-5-156, are based on the sequence of hGHRH , which is the shortest fully active fragment of the native hGHRH (1-3) . The amino acid substitutions present in JV-1-42, such as Phe(4-Cl) 6 , Arg , and therefore this analog can be selectively radiolabeled on the Tyr 10 residue, whereas His 1 will not react. RT-PCR analyses revealed the expression of splice variants of hGHRH receptors in CAKI-1 RCC. Similar splice variants were also found in other normal and malignant human extrapituitary cells as presented in detail in the accompanying publication (36) . However additional studies are needed for the identification of the protein structure of these GHRH receptor isoforms in human cancers.
The pituitary GHRH receptor belongs to G-protein-coupled transmembrane receptor superfamily, which includes receptors for VIP and secretin (20) (21) (22) (23) . VIP and its antagonists can inhibit the proliferation of various human carcinomas in vivo and in vitro through VIP receptors expressed on cancer cells (24) (25) (26) . Although considerable structural homology exists between GHRH and VIP peptides as well as between their receptors, our recent work shows that the antiproliferative effect of GHRH antagonists such as JV-1-36, JV-1-38, and JV-1-42 is exerted through a mechanism independent of VIP receptors (27) . High-affinity receptors for VIP are also present on CAKI-1 RCC, but our work clearly demonstrates that these receptors do not recognize hGHRH and its analogs and display markedly lower or almost negligible binding to GHRH antagonists such as JV-1-42. The biodistribution studies show significant tumor uptake 60 min after the injection of 125 I-JV-1-42, confirming in vitro GHRH receptor findings. The increase in uptake of the radioligand in CAKI-1 tumors appears to be mediated by GHRH receptors, since VIP receptor-positive tissues such as lung and small intestine displayed decreasing or unchanged radioactivities.
This study also shows that treatment of orthotopically implanted CAKI-1 RCC with a potent GHRH antagonist, JV-1-38, significantly inhibits the growth of primary and metastatic lesions. This finding is in good agreement with a previous study indicating a suppression of growth of s.c. xenografts of CAKI-1 RCC with an early GHRH antagonist, MZ-4-71 (10) . The present results suggest that, in addition to previously demonstrated endocrine action of GHRH antagonists based on inhibition of GH͞IGF-I axis, antitumor effects of these analogs can be exerted directly through GHRH receptors expressed by CAKI-1 RCC.
In conclusion, the ligand binding studies described herein, combined with the evidence from the isolation and sequencing of cDNA encoding receptor splice variants reported in the accompanying publication (36) , indicate that the receptors on various tumors that bind GHRH antagonists are distinct from the pituitary GHRH receptors.
